Discover study in the argentine population

Authors

  • Dafne Walter Faculty of Medicine, University of Buenos Aires, Autonomous City of Buenos Aires
  • Gustavo Fretchel Hospital de Clínicas José de San Martín, Sirio Libanés Hospital, Autonomous City of Buenos Aires, Argentina
  • Silvia Gorbán de Lapertosa Faculty of Medicine, National University of the Northeast (UNNE), Corrientes, Argentina
  • Víctor Commendatore National University of the Northeast (UNNE), San Martín de Paraná Hospital, Paraná, Entre Ríos
  • Alejandro Chertkoff Diabetological Medical Center (CEMEDIAB), Autonomous City of Buenos Aires, Argentina
  • Adriana Villarino National University of Córdoba, DAMIC Medical Institute/Rusculleda Foundation, Córdoba, Argentina
  • Graciela Fuentes Carlos Durand Hospital, Dra. Fuente Medical Office, Autonomous City of Buenos Aires, Argentina

DOI:

https://doi.org/10.47196/diab.v54i2.243

Keywords:

type 2 diabetes mellitus, treatment;, therapeutic inertia, cardiovascular risk factors

Abstract

Introduction: type 2 diabetes mellitus (T2DM) is a highly prevalent metabolic disease, which constitutes an important cardiovascular risk factor, in which patients are not only diagnosed late, but remain for prolonged times, with glycemic and other cardiovascular risk factors poorly controlled. There is a significant therapeutic inertia in the implementation of antidiabetic drugs in the second line of treatment.

Objectives: the main objective of the DISCOVER study was to provide realworld data to assess antidiabetic therapy and prospective clinical outcomes in patients with T2DM who initiate a second line pharmacological therapy for blood glucose reduction. The secondary objective was to obtain data from Argentina on glycemic control, metabolic control, comorbidities, cardiovascular risk factors and the concomitant therapeutic approach compared to the global world.

Materials and methods: DISCOVER is a prospective 3 year observational study in which patients from 37 countries with T2DM with poor glycemic control who required second line antidiabetic therapy were involved. Argentina participated with 14 urban centers. Inclusion criteria were: patients with a diagnosis of T2DM over 18 years of age who require a second line of treatment for glycemic control after oral first line treatment, with monotherapy, or double or triple therapy administered as a fixed dose combination.

Results: Argentina data are presented. 299 patients with a diagnosis of T2DM, were enrolled (51.3% men) who were outside the objective of glycemic control (glycemic control was established according to the HbA1c value of <7% according to the criteria of the American Diabetes Association, ADA 2020). Mean age was 59 years±10 years. The mean HbA1c value was 8.8%±1.9% with an average fasting glucose of 182.9 mg/dl±59.6 mg/dl. An average body mass index (BMI) of 32.2kg/m2±6.0 kg/m2was recorded. Argentina had a high percentage of subjects over 25 years with high BMI (90%). A high percentage of lipids parameters were outside the con-trol objectives for diabetic patients. The ADA 2020 guidelines recommends the use of moderately potent statin with the following LDL colesterol (LDLc) values <100 mg/dl for patients without cardiovascular disease and LDLc <70 mg/dl for patients with cardiovascular disease and use of high potency statin and trygliceride values <150 mg/dl following the criteria ADA 2020 guidelines. The average total cholesterol values were 188 mg/dl±44 mg/dl, for LDLc 114.39 mg/dl±10 mg/dl. Triglycerides with a mean 180.1 mg/dl±97.6 mg/dl. A two year follow up showed a statistically significant decrease in blood glucose and HbA1c levels, as well as lipids para-meters, although the recommended treatment goals were not achieved, in despite of which only 25% of patients received statin treatment. The most used antidiabetic drugs in the second line were sulfonylureas and DPP-4 inhibitors.

Conclusions: a high degree of inertia was recognized in terms of progression to establish a second line of treatment, based on the high level of HbA1c with which it was initiated. This study showed the situation of metabolic control, associated cardiovascular risk factors and the treatment of T2DM in the real world of our country. Necessary measures must be taken in order to improve the parameters presented and they must be able to be evaluated with studies similar to the current one. It is important to continue working to prevent the progression of diabetes toward chronic complications in those patients who have already developed the disease.

Author Biographies

Dafne Walter, Faculty of Medicine, University of Buenos Aires, Autonomous City of Buenos Aires

Physician specializing in Internal Medicine and Nutrition-Diabetes, Faculty of Medicine, University of Buenos Aires; Medical Scientific Liaison CVRM AstraZeneca

Gustavo Fretchel, Hospital de Clínicas José de San Martín, Sirio Libanés Hospital, Autonomous City of Buenos Aires, Argentina

Medical specialist in Nutrition, Doctorate at the University of Buenos Aires (UBA); Head of Nutrition at the José de San Martín Hospital de Clínicas; Head of Diabetes at the Syrian Lebanese Hospital

Silvia Gorbán de Lapertosa, Faculty of Medicine, National University of the Northeast (UNNE), Corrientes, Argentina

Senior Professor of Nutrition and Health Education, Faculty of Medicine, National University of the Northeast (UNNE)

Víctor Commendatore, National University of the Northeast (UNNE), San Martín de Paraná Hospital, Paraná, Entre Ríos

Master/Director of the initial and advanced Diplomas of the Argentine Diabetes Society (SAD), Universidad Nacional del Nordeste (UNNE) 2019; Head of the Endocrinology, Diabetes and Nutrition Service of the San Martín de Paraná Hospital

Alejandro Chertkoff, Diabetological Medical Center (CEMEDIAB), Autonomous City of Buenos Aires, Argentina

Diabetologist and Nutritionist; Medical Director of the Diabetolgócio Medical Center (CEMEDIAB)

Adriana Villarino, National University of Córdoba, DAMIC Medical Institute/Rusculleda Foundation, Córdoba, Argentina

Physician specializing in Diabetology, National University of Córdoba, specialist in Internal Medicine; University Professor; Head of the Diabetes Area, DAMIC Medical Institute/Rusculleda Foundation

Graciela Fuentes, Carlos Durand Hospital, Dra. Fuente Medical Office, Autonomous City of Buenos Aires, Argentina

Medical specialist in Nutrition and specialized in Diabetes; Consultant of the Nutrition Unit of the Carlos Durand Hospital, Dr. Fuente Medical Office; Coordinator of the DISCOVER Study in Argentina

Published

2023-01-10

How to Cite

Walter, D., Fretchel, G., Gorbán de Lapertosa, S., Commendatore, V., Chertkoff, A., Villarino, A., & Fuentes, G. (2023). Discover study in the argentine population. Journal of the Argentine Society of Diabetes, 54(2), 31–38. https://doi.org/10.47196/diab.v54i2.243

Issue

Section

Original article

Most read articles by the same author(s)

<< < 1 2 3